CSF3 and Decreased total neutrophil count: A second protocol amendment was therefore implemented by allowing the therapeutic use of G-CSF to manage febrile neutropenia if grade 4 neutropenia, or grade 3 neutropenia complicated by a temperature ≥ 38 °C, were observed.